MaxLinear (MXL) has had the highest return since March 27, 2026 by a mid-cap US stock, returning 362.9%.
| ASSET | % RETURN |
|---|---|
MaxLinear (MXL) | 362.88% |
Iovance Biotherapeutics (IOVA) | 302.19% |
CareDx (CDNA) | 284.52% |
Abcellera Biologics (ABCL) | 283.08% |
10X Genomics (TXG) | 260.69% |
Penguin Solutions (PENG) | 255.52% |
AMC Entertainment (AMC) | 211.34% |
Twist Bioscience (TWST) | 210.13% |
Gitlab (GTLB) | 168.94% |
BlackBerry (BB) | 167.69% |
GRAIL, LLC (GRAL) | 165.61% |
Hinge Health (HNGE) | 162.4% |
Clover Health Investments (CLOV) | 161.45% |
Strive (ASST) | 156.5% |
Xometry (XMTR) | 147.92% |
Netskope, Inc Class A Common Stock (NTSK) | 146.39% |
Fortrea (FTRE) | 141.71% |
Amplitude (AMPL) | 140.94% |
Five9 (FIVN) | 137.48% |
Sellas Life Sciences (SLS) | 134.3% |
Maravai Lifesciences Holdings (MRVI) | 131.05% |
Insight Enterprises (NSIT) | 130.83% |
Organon (OGN) | 126.24% |
NeoGenomics (NEO) | 124.32% |
Maase (MAAS) | 122.01% |
Mid-cap stocks are treated as having a market cap between $2B and $10B.